Management of the Patient with a Malignant Pleural Effusion

ABSTRACT

A malignant pleural effusion (MPE) establishes an incurable stage of a malignancy. Median survival after detection of an MPE is 4 to 6 months in general populations of patients with cancer. Management of MPE centers on palliation of symptoms because no available treatments prolong survival. Mismanagement of MPE, however, can shorten survival and add to patients' burden of disease. Appropriate management requires a multidisciplinary approach with competency in existing treatment modalities to allow individualization of care. Although few prospective studies exist to guide clinical decisions, treating centers should present to patients the relative risks and benefits of different approaches and ensure that their institution's clinical outcomes in managing MPE match those of best clinical practices reported in the literature. Treatment of MPE is moving toward less interventional approaches that can manage patients in ambulatory settings thereby decreasing cost, discomfort, and time away from home for inpatient care.

Malignant pleural effusion - pleural disease - cancer - pleurodesis

REFERENCES

• 1 Heffner J E, Nietert P J, Barbieri C. Pleural fluid pH as a predictor of survival for patients with malignant pleural effusions.  Chest. 2000;  117 79-86
• 2 Gonzalez A V, Bezwada V, Beamis Jr JFJ, Villanueva A G. Lung injury following thoracoscopic talc insufflation: experience of a single North American center.  Chest. 2010;  137 1375-1381
• 3 Goldstraw P, Crowley J, Chansky K International Association for the Study of Lung Cancer International Staging Committee et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.  J Thorac Oncol. 2007;  2 706-714
• 4 Heffner J E. Diagnosis and management of malignant pleural effusions.  Respirology. 2008;  13 5-20
• 5 Kolschmann S, Ballin A, Gillissen A. Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions.  Chest. 2005;  128 1431-1435
• 6 Rubio E R, Chang E E, Kovitz K L. Thoracoscopic management of pleural effusions in Kaposi's sarcoma: a rapid and effective alternative for diagnosis and treatment.  South Med J. 2002;  95 919-921
• 7 Fujita A, Takabatake H, Tagaki S, Sekine K. Combination chemotherapy in patients with malignant pleural effusions from non-small cell lung cancer: cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony-stimulating factor support.  Chest. 2001;  119 340-343
• 8 Matsumoto Y, Nomura K, Ueda K et al.. Human herpesvirus 8-negative malignant effusion lymphoma: a distinct clinical entity and successful treatment with rituximab.  Leuk Lymphoma. 2005;  46 415-419
• 9 Das S K, Saha S K, Das A, Halder A K, Banerjee S N, Chakraborty M. A study of comparison of efficacy and safety of talc and povidone iodine for pleurodesis of malignant pleural effusions.  J Indian Med Assoc. 2008;  106 589-590, 592
• 10 Dresler C M, Olak J, Herndon II J E Cooperative Groups Cancer and Leukemia Group B et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion.  Chest. 2005;  127 909-915
• 11 Ozyurtkan M O, Balci A E, Cakmak M. Predictors of mortality within three months in the patients with malignant pleural effusion.  Eur J Intern Med. 2010;  21 30-34
• 12 Das D K. Serous effusions in malignant lymphomas: a review.  Diagn Cytopathol. 2006;  34 335-347
• 13 Villena V, Pérez V, Pozo F et al.. Amylase levels in pleural effusions: a consecutive unselected series of 841 patients.  Chest. 2002;  121 470-474
• 14 Bielsa S, Salud A, Martínez M et al.. Prognostic significance of pleural fluid data in patients with malignant effusion.  Eur J Intern Med. 2008;  19 334-339
• 15 Bielsa S, Esquerda A, Salud A et al.. High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions.  Eur J Intern Med. 2009;  20 383-386
• 16 Jiménez D, Díaz G, Gil D et al.. Etiology and prognostic significance of massive pleural effusions.  Respir Med. 2005;  99 1183-1187
• 17 Duysinx B, Corhay J L, Larock M P et al.. Prognostic value of metabolic imaging in non-small cell lung cancers with neoplasic pleural effusion.  Nucl Med Commun. 2008;  29 982-986
• 18 Burrows C M, Mathews W C, Colt H G. Predicting survival in patients with recurrent symptomatic malignant pleural effusions: an assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease.  Chest. 2000;  117 73-78
• 19 Bernard A, de Dompsure R B, Hagry O, Favre J P. Early and late mortality after pleurodesis for malignant pleural effusion.  Ann Thorac Surg. 2002;  74 213-217
• 20 Steger V, Mika U, Toomes H et al.. Who gains most? A 10-year experience with 611 thoracoscopic talc pleurodeses.  Ann Thorac Surg. 2007;  83 1940-1945
• 21 Heidecker J, Huggins J T, Sahn S A, Doelken P. Pathophysiology of pneumothorax following ultrasound-guided thoracentesis.  Chest. 2006;  130(4) 1173-1184
• 22 Ponrartana S, Laberge J M, Kerlan R K, Wilson M W, Gordon R L. Management of patients with “ex vacuo” pneumothorax after thoracentesis.  Acad Radiol. 2005;  12 980-986
• 23 Feller-Kopman D. Therapeutic thoracentesis: the role of ultrasound and pleural manometry.  Curr Opin Pulm Med. 2007;  13 312-318
• 24 Huggins J T, Sahn S A, Heidecker J, Ravenel J G, Doelken P. Characteristics of trapped lung: pleural fluid analysis, manometry, and air-contrast chest CT.  Chest. 2007;  131 206-213
• 25 Heffner J E, Nietert P J, Barbieri C. Pleural fluid pH as a predictor of pleurodesis failure: analysis of primary data.  Chest. 2000;  117 87-95
• 26 Heffner J E, Heffner J N, Brown L K. Multilevel and continuous pleural fluid pH likelihood ratios for evaluating malignant pleural effusions.  Chest. 2003;  123 1887-1894
• 27 Crnjac A, Sok M, Kamenik M. Impact of pleural effusion pH on the efficacy of thoracoscopic mechanical pleurodesis in patients with breast carcinoma.  Eur J Cardiothorac Surg. 2004;  26 432-436
• 28 Antunes G, Neville E, Duffy J, Ali N. Pleural Diseases Group, Standards of Care Committee, British Thoracic Society . BTS guidelines for the management of malignant pleural effusions.  Thorax. 2003;  58(Suppl 2) ii29-ii38
• 29 Marrazzo A, Noto A, Casà L et al.. Video-thoracoscopic surgical pleurodesis in the management of malignant pleural effusion: the importance of an early intervention.  J Pain Symptom Manage. 2005;  30 75-79
• 30 Barnes T W, Morgenthaler T I, Olson E J, Hesley G K, Decker P A, Ryu J H. Sonographically guided thoracentesis and rate of pneumothorax.  J Clin Ultrasound. 2005;  33 442-446
• 31 Huggins J T, Doelken P. Pleural manometry.  Clin Chest Med. 2006;  27 229-240
• 32 Feller-Kopman D, Walkey A, Berkowitz D, Ernst A. The relationship of pleural pressure to symptom development during therapeutic thoracentesis.  Chest. 2006;  129 1556-1560
• 33 Maskell N A, Butland R J. Pleural Diseases Group, Standards of Care Committee, British Thoracic Society . BTS guidelines for the investigation of a unilateral pleural effusion in adults.  Thorax. 2003;  58(Suppl 2) ii8-ii17
• 34 Lee Y C, Baumann M H, Maskell N A et al.. Pleurodesis practice for malignant pleural effusions in five English-speaking countries: survey of pulmonologists.  Chest. 2003;  124 2229-2238
• 35 Medford A R, Maskell N A. A national survey of oncologist and chest physicians' attitudes towards empirical anti-oestrogen therapy, early pleurodesis and preference of sclerosing agent in malignant breast and ovarian pleural disease.  Palliat Med. 2005;  19 430-431
• 36 Saffran L, Ost D E, Fein A M, Schiff M J. Outpatient pleurodesis of malignant pleural effusions using a small-bore pigtail catheter.  Chest. 2000;  118 417-421
• 37 Sartori S, Tombesi P, Tassinari D et al.. Sonographically guided small-bore chest tubes and sonographic monitoring for rapid sclerotherapy of recurrent malignant pleural effusions.  J Ultrasound Med. 2004;  23 1171-1176
• 38 Caglayan B, Torun E, Turan D et al.. Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube.  Ann Surg Oncol. 2008;  15 2594-2599
• 39 Spiegler P A, Hurewitz A N, Groth M L. Rapid pleurodesis for malignant pleural effusions.  Chest. 2003;  123 1895-1898
• 40 Yildirim E, Dural K, Yazkan R et al.. Rapid pleurodesis in symptomatic malignant pleural effusion.  Eur J Cardiothorac Surg. 2005;  27 19-22
• 41 Marom E M, Erasmus J J, Herndon II J E, Zhang C, McAdams H P. Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions.  AJR Am J Roentgenol. 2002;  179 105-108
• 42 Terra R M, Junqueira J J, Teixeira L R, Vargas F S, Pêgo-Fernandes P M, Jatene F B. Is full postpleurodesis lung expansion a determinant of a successful outcome after talc pleurodesis?.  Chest. 2009;  136 361-368
• 43 Mager H J, Maesen B, Verzijlbergen F, Schramel F. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis.  Lung Cancer. 2002;  36 77-81
• 44 Dryzer S R, Allen M L, Strange C, Sahn S A. A comparison of rotation and nonrotation in tetracycline pleurodesis.  Chest. 1993;  104 1763-1766
• 45 Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review.  Eur J Cardiothorac Surg. 2006;  29 829-838
• 46 Teixeira L R, Vargas F S, Acencio M M et al.. Influence of antiinflammatory drugs (methylprednisolone and diclofenac sodium) on experimental pleurodesis induced by silver nitrate or talc.  Chest. 2005;  128 4041-4045
• 47 Teixeira L R, Wu W, Chang D S, Light R W. The effect of corticosteroids on pleurodesis induced by doxycycline in rabbits.  Chest. 2002;  121 216-219
• 48 Xie C, Teixeira L R, McGovern J P, Light R W. Systemic corticosteroids decrease the effectiveness of talc pleurodesis.  Am J Respir Crit Care Med. 1998;  157(5 Pt 1) 1441-1444
• 49 Haddad F J, Younes R N, Gross J L, Deheinzelin D. Pleurodesis in patients with malignant pleural effusions: talc slurry or bleomycin? Results of a prospective randomized trial.  World J Surg. 2004;  28 749-753, discussion 753–754
• 50 Goodman A, Davies C W. Efficacy of short-term versus long-term chest tube drainage following talc slurry pleurodesis in patients with malignant pleural effusions: a randomised trial.  Lung Cancer. 2006;  54 51-55
• 51 Arapis K, Caliandro R, Stern J B, Girard P, Debrosse D, Gossot D. Thoracoscopic palliative treatment of malignant pleural effusions: results in 273 patients.  Surg Endosc. 2006;  20 919-923
• 52 Brega-Massone P P, Lequaglie C, Magnani B, Ferro F, Cataldo I. Chemical pleurodesis to improve patients' quality of life in the management of malignant pleural effusions: the 15 year experience of the National Cancer Institute of Milan.  Surg Laparosc Endosc Percutan Tech. 2004;  14 73-79
• 53 Cardillo G, Facciolo F, Carbone L et al.. Long-term follow-up of video-assisted talc pleurodesis in malignant recurrent pleural effusions.  Eur J Cardiothorac Surg. 2002;  21 302-305, discussion 305–306
• 54 Crnjac A. The significance of thoracoscopic mechanical pleurodesis for the treatment of malignant pleural effusions.  Wien Klin Wochenschr. 2004;  116(Suppl 2) 28-32
• 55 Debeljak A, Kecelj P, Triller N et al.. Talc pleurodesis: comparison of talc slurry instillation with thoracoscopic talc insufflation for malignant pleural effusions.  J BUON. 2006;  11 463-467
• 56 Gasparri R, Leo F, Veronesi G et al.. Video-assisted management of malignant pleural effusion in breast carcinoma.  Cancer. 2006;  106 271-276
• 57 Trotter D, Aly A, Siu L, Knight S. Video-assisted thoracoscopic (VATS) pleurodesis for malignant effusion: an Australian teaching hospital's experience.  Heart Lung Circ. 2005;  14 93-97
• 58 Casal R F, Eapen G A, Morice R C, Jimenez C A. Medical thoracoscopy.  Curr Opin Pulm Med. 2009;  15 313-320
• 59 Law W L, Chan J W, Lee S et al.. Pleuroscopy: our initial experience in Hong Kong.  Hong Kong Med J. 2008;  14 178-184
• 60 Lee P, Colt H G. Rigid and semirigid pleuroscopy: the future is bright.  Respirology. 2005;  10 418-425
• 61 Ernst A, Hersh C P, Herth F et al.. A novel instrument for the evaluation of the pleural space: an experience in 34 patients.  Chest. 2002;  122 1530-1534
• 62 Munavvar M, Khan M A, Edwards J, Waqaruddin Z, Mills J. The autoclavable semirigid thoracoscope: the way forward in pleural disease?.  Eur Respir J. 2007;  29 571-574
• 63 Katlic M R. Video-assisted thoracic surgery utilizing local anesthesia and sedation.  Eur J Cardiothorac Surg. 2006;  30 529-532
• 64 Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions.  Cochrane Database Syst Rev. 2004;  (1) CD002916
• 65 Schulze M, Boehle A S, Kurdow R, Dohrmann P, Henne-Bruns D. Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients.  Ann Thorac Surg. 2001;  71 1809-1812
• 66 Ukale V, Agrenius V, Hillerdal G, Mohlkert D, Widström O. Pleurodesis in recurrent pleural effusions: a randomized comparison of a classical and a currently popular drug.  Lung Cancer. 2004;  43 323-328
• 67 Paschoalini MdaS, Vargas F S, Marchi E et al.. Prospective randomized trial of silver nitrate vs talc slurry in pleurodesis for symptomatic malignant pleural effusions.  Chest. 2005;  128 684-689
• 68 Kuzdzał J, Sładek K, Wasowski D et al.. Talc powder vs doxycycline in the control of malignant pleural effusion: a prospective, randomized trial.  Med Sci Monit. 2003;  9 PI54-PI59
• 69 Ong K C, Indumathi V, Raghuram J, Ong Y Y. A comparative study of pleurodesis using talc slurry and bleomycin in the management of malignant pleural effusions.  Respirology. 2000;  5 99-103
• 70 Brant A, Eaton T. Serious complications with talc slurry pleurodesis.  Respirology. 2001;  6 181-185
• 71 de Campos J R, Vargas F S, de Campos Werebe E et al.. Thoracoscopy talc poudrage: a 15-year experience.  Chest. 2001;  119 801-806
• 72 Bouchama A, Chastre J, Gaudichet A, Soler P, Gibert C. Acute pneumonitis with bilateral pleural effusion after talc pleurodesis.  Chest. 1984;  86 795-797
• 73 Peek H, van der Bruggen W, Limonard G. Pleural FDG uptake more than a decade after talc pleurodesis.  Case Report Med. 2009;  2009 650864
• 74 Ahmadzadehfar H, Palmedo H, Strunk H, Biersack H J, Habibi E, Ezziddin S. False positive 18F-FDG-PET/CT in a patient after talc pleurodesis.  Lung Cancer. 2007;  58 418-421
• 75 Ferrer J, Montes J F, Villarino M A, Light R W, García-Valero J. Influence of particle size on extrapleural talc dissemination after talc slurry pleurodesis.  Chest. 2002;  122 1018-1027
• 76 Froudarakis M E, Klimathianaki M, Pougounias M. Systemic inflammatory reaction after thoracoscopic talc poudrage.  Chest. 2006;  129 356-361
• 77 Rossi V F, Vargas F S, Marchi E et al.. Acute inflammatory response secondary to intrapleural administration of two types of talc.  Eur Respir J. 2010;  35 396-401
• 78 Viallat J R, Rey F, Astoul P, Boutin C. Thoracoscopic talc poudrage pleurodesis for malignant effusions: a review of 360 cases.  Chest. 1996;  110 1387-1393
• 79 Weissberg D, Ben-Zeev I. Talc pleurodesis: experience with 360 patients.  J Thorac Cardiovasc Surg. 1993;  106 689-695
• 80 Noppen M. Who's (still) afraid of talc?.  Eur Respir J. 2007;  29 619-621
• 81 Janssen J P, Collier G, Astoul P et al.. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study.  Lancet. 2007;  369 1535-1539
• 82 Kuzniar T J, Blum M G, Kasibowska-Kuzniar K, Mutlu G M. Predictors of acute lung injury and severe hypoxemia in patients undergoing operative talc pleurodesis.  Ann Thorac Surg. 2006;  82 1976-1981
• 83 Dikensoy O, Light R W. Alternative widely available, inexpensive agents for pleurodesis.  Curr Opin Pulm Med. 2005;  11 340-344
• 84 van den Toorn L M, Schaap E, Surmont V F, Pouw E M, van der Rijt K C, van Klaveren R J. Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter.  Lung Cancer. 2005;  50 123-127
• 85 Putnam Jr J B, Light R W, Rodriguez R M et al.. A randomized comparison of indwelling pleural catheter and doxycycline pleurodesis in the management of malignant pleural effusions.  Cancer. 1999;  86 1992-1999
• 86 Putnam Jr J B, Walsh G L, Swisher S G et al.. Outpatient management of malignant pleural effusion by a chronic indwelling pleural catheter.  Ann Thorac Surg. 2000;  69 369-375
• 87 Pollak J S, Burdge C M, Rosenblatt M, Houston J P, Hwu W J, Murren J. Treatment of malignant pleural effusions with tunneled long-term drainage catheters.  J Vasc Interv Radiol. 2001;  12 201-208
• 88 Tremblay A, Michaud G. Single-center experience with 250 tunnelled pleural catheter insertions for malignant pleural effusion.  Chest. 2006;  129 362-368
• 89 Pien G W, Gant M J, Washam C L, Sterman D H. Use of an implantable pleural catheter for trapped lung syndrome in patients with malignant pleural effusion.  Chest. 2001;  119 1641-1646
• 90 Musani A I, Haas A R, Seijo L, Wilby M, Sterman D H. Outpatient management of malignant pleural effusions with small-bore, tunneled pleural catheters.  Respiration. 2004;  71 559-566
• 91 Ohm C, Park D, Vogen M et al.. Use of an indwelling pleural catheter compared with thorascopic talc pleurodesis in the management of malignant pleural effusions.  Am Surg. 2003;  69 198-202, discussion 202
• 92 Sioris T, Sihvo E, Salo J, Räsänen J, Knuuttila A. Long-term indwelling pleural catheter (PleurX) for malignant pleural effusion unsuitable for talc pleurodesis.  Eur J Surg Oncol. 2009;  35 546-551
• 93 Spector M, Pollak J S. Management of malignant pleural effusions.  Semin Respir Crit Care Med. 2008;  29 405-413
• 94 Thornton R H, Miller Z, Covey A M et al.. Tunneled pleural catheters for treatment of recurrent malignant pleural effusion following failed pleurodesis.  J Vasc Interv Radiol. 2010;  21 696-700
• 95 Efthymiou C A, Masudi T, Thorpe J A, Papagiannopoulos K. Malignant pleural effusion in the presence of trapped lung: five-year experience of PleurX tunnelled catheters.  Interact Cardiovasc Thorac Surg. 2009;  9 961-964
• 96 Warren W H, Kim A W, Liptay M J. Identification of clinical factors predicting PleurX catheter removal in patients treated for malignant pleural effusion.  Eur J Cardiothorac Surg. 2008;  33 89-94
• 97 Warren W H, Kim A W, Liptay M J. Identification of clinical factors predicting PleurX catheter removal in patients treated for malignant pleural effusion.  Eur J Cardiothorac Surg. 2008;  33 89-94
• 98 Pollak J S. Malignant pleural effusions: treatment with tunneled long-term drainage catheters.  Curr Opin Pulm Med. 2002;  8 302-307
• 99 Murthy S C, Okereke I, Mason D P, Rice T W. A simple solution for complicated pleural effusions.  J Thorac Oncol. 2006;  1 697-700
• 100 Warren W. Talc pleurodesis for malignant pleural effusions is preferred over the PleurX catheter (contrary position).  Ann Surg Oncol. 2007;  14 2700-2701
• 101 Stather D R, Tremblay A. Use of tunneled pleural catheters for outpatient treatment of malignant pleural effusions.  Curr Opin Pulm Med. 2007;  13 328-333
• 102 Bazerbashi S, Villaquiran J, Awan M Y, Unsworth-White M J, Rahamim J, Marchbank A. Ambulatory intercostal drainage for the management of malignant pleural effusion: a single center experience.  Ann Surg Oncol. 2009;  16 3482-3487
• 103 Olden A M, Holloway R. Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis.  J Palliat Med. 2010;  13 59-65
• 104 Antevil J L, Putnam Jr JBJ. Talc pleurodesis for malignant effusions is preferred over the pleurx catheter (pro position).  Ann Surg Oncol. 2007;  14 2698-2699
• 105 Wachsman A M, Hoffer E K, Forauer A R, Silas A M, Gemery J M. Tension pneumothorax after placement of a tunneled pleural drainage catheter in a patient with recurrent malignant pleural effusions.  Cardiovasc Intervent Radiol. 2007;  30 531-533
• 106 Janes S M, Rahman N M, Davies R J, Lee Y C. Catheter-tract metastases associated with chronic indwelling pleural catheters.  Chest. 2007;  131 1232-1234
• 107 Genc O, Petrou M, Ladas G, Goldstraw P. The long-term morbidity of pleuroperitoneal shunts in the management of recurrent malignant effusions.  Eur J Cardiothorac Surg. 2000;  18 143-146
• 108 Artemiou O, Marta G M, Klepetko W, Wolner E, Müller M R. Pleurovenous shunting in the treatment of nonmalignant pleural effusion.  Ann Thorac Surg. 2003;  76 231-233
• 109 American Academy of Hospice and Palliative Medicine . National Consensus Project for Quality Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary.  J Palliat Med. 2004;  7 611-627
• 110 Word Health Organization definition of palliative care. World Health Organization programmes and projects (online). 2010. Available at: http://www.who.int/cancer/palliative/definition/en/ Accessed November 17, 2010
• 111 Kilic D, Akay H, Kavukçu S et al.. Management of recurrent malignant pleural effusion with chemical pleurodesis.  Surg Today. 2005;  35 634-638
• 112 Stefani A, Natali P, Casali C, Morandi U. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion: a prospective comparative study.  Eur J Cardiothorac Surg. 2006;  30 827-832
• 113 Porcel J M, Salud A, Nabal M, Vives M, Esquerda A, Rodríguez-Panadero F. Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions.  Support Care Cancer. 2006;  14 475-478
• 114 Heffner J E, Standerfer R J, Torstveit J, Unruh L. Clinical efficacy of doxycycline for pleurodesis.  Chest. 1994;  105 1743-1747
• 115 Sartori S, Tassinari D, Ceccotti P et al.. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions.  J Clin Oncol. 2004;  22 1228-1233
• 116 Moffett M J, Ruckdeschel J C. Bleomycin and tetracycline in malignant pleural effusions: a review.  Semin Oncol. 1992;  19(2, Suppl 5) 59-62, discussion 62–63
• 117 Stiksa G, Korsgaard R, Simonsson B G. Treatment of recurrent pleural effusion by pleurodesis with quinacrine: comparison between instillation by repeated thoracenteses and by tube drainage.  Scand J Respir Dis. 1979;  60 197-205
• 118 Bayly T C, Kisner D L, Sybert A, Macdonald J S, Tsou E, Schein P S. Tetracycline and quinacrine in the control of malignant pleural effusions: a randomized trial.  Cancer. 1978;  41 1188-1192
• 119 Koldsland S, Svennevig J L, Lehne G, Johnson E. Chemical pleurodesis in malignant pleural effusions: a randomised prospective study of mepacrine versus bleomycin.  Thorax. 1993;  48 790-793
• 120 Banerjee A K, Willetts I, Robertson J F, Blamey R W. Pleural effusion in breast cancer: a review of the Nottingham experience.  Eur J Surg Oncol. 1994;  20 33-36
• 121 Olivares-Torres C A, Laniado-Laborín R, Chávez-García C, León-Gastelum C, Reyes-Escamilla A, Light R W. Iodopovidone pleurodesis for recurrent pleural effusions.  Chest. 2002;  122 581-583
• 122 Agarwal R, Aggarwal A N, Gupta D. Efficacy and safety of iodopovidone pleurodesis through tube thoracostomy.  Respirology. 2006;  11 105-108
• 123 Agarwal R, Aggarwal A N, Gupta D, Jindal S K. Efficacy and safety of iodopovidone in chemical pleurodesis: a meta-analysis of observational studies.  Respir Med. 2006;  100 2043-2047
• 124 Kelly-Garcia J, Roman-Berumen J F, Ibarra-Perez C. Iodopovidone and bleomycin pleurodesis for effusions due to malignant epithelial neoplasms.  Arch Med Res. 1997;  28 583-585
• 125 Agarwal R. Iodopovidone: an inexpensive and effective agent for chemical pleurodesis.  Lung Cancer. 2007;  55 253-254
• 126 Dey A, Bhuniya S, Datta Chaudhuri A et al.. Iodopovidone pleurodesis: experience of a tertiary hospital in Kolkata.  Singapore Med J. 2010;  51 163-165
• 127 Foresti V. Intrapleural Corynebacterium parvum for recurrent malignant pleural effusions.  Respiration. 1995;  62 21-26
• 128 Hillerdal G, Kiviloog J, Nöu E, Steinholtz L. Corynebacterium parvum in malignant pleural effusion: a randomized prospective study.  Eur J Respir Dis. 1986;  69 204-206
• 129 McLeod D T, Calverley P M, Millar J W, Horne N W. Further experience of Corynebacterium parvum in malignant pleural effusion.  Thorax. 1985;  40 515-518
• 130 Senyiğit A, Bayram H, Babayiğit C, Topçu F, Balci A E, Satici O. Comparison of the effectiveness of some pleural sclerosing agents used for control of effusions in malignant pleural mesothelioma: a review of 117 cases.  Respiration. 2000;  67 623-629
• 131 Chella A, Ribechini A, Dini P, Adamo C, Mussi A, Angeletti C A. Treatment of malignant pleural effusion by percutaneous catheter drainage and chemical pleurodesis.  [in Italian] Minerva Chir. 1994;  49(11) 1077-1082
• 132 Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer.  World J Surg Oncol. 2004;  2 16
• 133 Barbetakis N, Vassiliadis M, Kaplanis K, Valeri R, Tsilikas C. Mitoxantrone pleurodesis to palliate malignant pleural effusion secondary to ovarian cancer.  BMC Palliat Care. 2004;  3 4
• 134 Kelly J, Holmes E C, Rosen G. Mitoxantrone for malignant pleural effusion due to metastatic sarcoma.  Surg Oncol. 1993;  2 299-301
• 135 Wilkins III H E, Connolly M M, Grays P, Marquez G, Nelson D. Recombinant interferon alpha-2b in the management of malignant pleural effusions.  Chest. 1997;  111 1597-1599
• 136 Sartori S, Trevisani L, Nielsen I, Tassinari D, Abbasciano V. Intracavitary bleomycin vs interferon in the management of malignant pleural effusions.  Chest. 1998;  113 1145-1146
• 137 Ren S, Terman D S, Bohach G et al.. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer.  Chest. 2004;  126 1529-1539
• 138 Kasahara K, Shibata K, Shintani H et al.. Randomized phase II trial of OK-432 in patients with malignant pleural effusion due to non-small cell lung cancer.  Anticancer Res. 2006;  26 1495-1499
• 139 Luh K T, Yang P C, Kuo S H, Chang D B, Yu C J, Lee L N. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial.  Cancer. 1992;  69 674-679